ANN ARBOR ? Biopharmaceutcal company NanoBio has hired a new executive, Stephen Gracon, D.V.M., as vice president of regulatory affairs. Dr. Gracon will lead the regulatory and quality assurance activities for the company’s pipeline of anti-infective products and mucosal vaccines.
Dr. Gracon brings 30 years of experience to NanoBio in diverse areas within the pharmaceutical industry, including pathology and experimental toxicology, clinical research, and regulatory affairs within the United States and internationally. Dr. Gracon served in various clinical, research and regulatory positions at Parke-Davis, Pfizer, Amgen and Baxter prior to joining NanoBio.
He has a unique combination of experience with both small and large molecules in a broad range of indications, as well as with seasonal and pandemic vaccines and plasma-derived products.
?We are very fortunate to have Dr. Gracon?s extensive regulatory experience as we prepare for multiple regulatory submissions,? said James Baker Jr., M.D., founder and CSO of NanoBio Corporation. ?His specialized knowledge of regulatory protocol for both therapeutics and vaccines will be critical to moving NanoBio?s products to FDA approval.?
For more information, click on NanoBio.Com
a>>
